Dr Zarnie Lwin gives an overview of the interim findings of the LEAP-005 trial that were presented at the Virtual 2020 ESMO Congress, and the rationale for combining lenvatinib plus pembrolizumab for the treatment of solid tumours. The late-breaking abstract ‘LEAP-005: Phase 2 Study of Lenvatinib (Len) Plus Pembrolizumab (Pembro) in Patients (Pts) With Previously Treated Advanced Solid Tumors’ (LBA41) was presented at the Virtual 2020 ESMO Congress, 19–21 September 2020.
- What is the rationale for the combined use of lenvatinib plus pembrolizumab in the treatment of advanced solid tumours? (0:17)
- Could you tell us a little about the aims and design of the LEAP-005 study? (1:30)
- What were the interim findings, and have the primary endpoints of objective response rate, safety and tolerability been met so far? (2:58)
- What are the remaining gaps in our knowledge and what is planned for the remainder of the study? (4:16)
Speaker Disclosure: Zarnie Lwin serves on the scientific advisory committee for LEAP 005 which is sponsored by Merck Sharpe and Dohme and has received honoraria for consulting, advisory roles or travel sponsorship by AbbVie, AstraZeneca, BMS, Roche and Merck.
Support: Interview and filming supported by Touch Medical Media Ltd. The LEAP-005 study was funded by Eisai Inc. and Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc., Kenilworth, NJ, USA.
Filmed in coverage of the Virtual 2020 ESMO Congress.
Share this Video
Related Videos In Immunotherapy
Leisha A Emens, ESMO 2020 – Overall Survival Analysis from IMpassion 130 in Triple-negative Breast Cancer
Prof. Leisha A Emens joins touchONCOLOGY to discuss the final overall survival analysis of the phase III IMpassion 130 study investigating atezolizumab plus nab-paclitaxel versus placebo plus nab-paclitaxel in previously untreated locally advanced or metastatic triple-negative breast cancer. Prof. Emens explores what we can learn from these findings, as well as the failure of IMpassion […]
Zarnie Lwin, ESMO 2020 – Lenvatinib Plus Pembrolizumab in Advanced Solid Tumors: Initial results from LEAP-005
Dr Zarnie Lwin gives an overview of the interim findings of the LEAP-005 trial that were presented at the Virtual 2020 ESMO Congress, and the rationale for combining lenvatinib plus pembrolizumab for the treatment of solid tumours. The late-breaking abstract ‘LEAP-005: Phase 2 Study of Lenvatinib (Len) Plus Pembrolizumab (Pembro) in Patients (Pts) With Previously […]
Ulka Vaishampayan, ESMO 2020 – ALKS 4230 Monotherapy and Data From the ARTISTRY-1 Trial
Dr Ulka Vaishampayan discusses how interleukin-2 may be used as a treatment for solid tumours and the potential role of the ALKS 4230 fusion protein due to its efficacy and safety profile. Data from the ARTISTRY-1 study was presented in the abstract ‘ALKS 4230 monotherapy and in combination with pembrolizumab (pembro) in patients (pts) with […]
Journal articles and more to your inbox
Get the latest clinical insights from touchONCOLOGYSign me up!